Bispecific Targeted Toxin DTATEGF Against Metastatic NSCLC Brain Tumors

Keyphrases

• Bispecific 100%
• Targeted Toxin 100%
• Brain Tumor 100%
• Metastatic Non-small Cell Lung Cancer 100%
• Diphtheria Toxin 100%
• Non-small Cell Lung Cancer (NSCLC) 66%
• Tumor 66%
• Convection-enhanced Delivery 66%
• Cerebral Tumor 66%
• Further Development 33%
• Cell Proliferation 33%
• Blood Vessels 33%
• Tumor Cells 33%
• Radiotherapy 33%
• Chemotherapy 33%
• Magnetic Resonance Imaging 33%
• Immunotoxin 33%
• Histological Analysis 33%
• Cancer Tumor 33%
• Epidermal Growth Factor Receptor 33%
• Neural Tissue 33%
• Metastatic Brain Tumor 33%
• Microgram 33%
• IC50 33%
• Treatment Group 33%
• Firefly Luciferase 33%
• Micrometastasis 33%
• Kaplan-Meier Survival Curves 33%
• Day 14 33%
• Survival Benefit 33%
• Eosin 33%
• Hematoxylin 33%
• Human Lung Cancer Cell Line 33%
• Non-small Cell Lung Cancer Cells 33%
• Luciferase Reporter Gene 33%
• MTT Assay 33%
• Stereotactic Radiosurgery 33%
• Focal Therapy 33%
• Mouse Xenograft Model 33%
• Bioluminescence Imaging 33%
• Osmotic Minipump 33%
• Soluble Urokinase Plasminogen Activator Receptor (suPAR) 33%
• Tumor Implantation 33%
• Human Non-small Cell Lung Cancer 33%
• Brain Tissue Samples 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Intracranial Tumor 100%
• Neoplasm 66%
• Diphtheria Toxin 50%
• Epidermal Growth Factor Receptor 33%
• Chemotherapy 16%
• Immunotoxin 16%
• Side Effect 16%
• Firefly Luciferase 16%
• IC50 16%
• Micrometastasis 16%
• Luciferase 16%
• Brain Metastasis 16%
• Eosin 16%
• Haematoxylin 16%
• Urokinase Receptor 16%